The MarketWatch News Department was not involved in the creation of this content. HONOLULU, Oct. 5, 2025 /PRNewswire/ -- An orally administered drug to redistribute excess iron and lower cellular ...
The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results